Revenue ($USD) : $4,030,400,000
R&D spend : $294,300,000
Employees : 6,990
Fiscal year end : 9/30/2023
CEO : Stephen MacMillan

www.hologic.com

Hologic in February 2024 announced FDA clearance of its Genius digital diagnostics system, which uses AI to enhance the detection of pre-cancerous lesions and cervical cancer cells. The company said its the first FDA-cleared digital cytology platform that combines deep learning-based AI with advanced volumetric imaging, marking an advancement in cervical cancer screening​. In July 2024, Hologic paid $310 million to acquire Endomagnetics, which specializes in breast surgery localization and lymphatic tracing technology. –CN

MORE ON MDO: How Hologic tapped AI and volumetric imaging for cytology